EYPT·July 17, 2026·litigation
EyePoint Agrees to Pay $4.7 Million to Settle Kickback Allegations Over Eye Drug DEXYCU
EyePoint will pay $4.7 million to resolve federal and state allegations that it paid kickbacks to ambulatory surgery centers to induce purchases of its post-cataract surgery drug DEXYCU, and has entered a five-year corporate integrity agreement with the HHS Office of Inspector General.